PTC Therapeutics (FRA:BH3) Moat Score: 5/10 (As of Jul. 09, 2026)


FRA:BH3 PTC Therapeutics Inc FRA:BH3
52 GF Score
Price €77.00
GF Value €31.18
! 9 Warning Signs
View Full Analysis

What is PTC Therapeutics Moat Score?

PTC Therapeutics FRA:BH3 +4.88% 52 Moat Score is 5 as of Jul. 09, 2026. GuruFocus rates FRA:BH3 with a GF Score™ of 52/100 and a GF Value™ of €31.18. The stock has 9 warning signs investors should review. Among 1,394 Biotechnology companies, PTC Therapeutics ranks better than 96.7% on this metric.

PTC Therapeutics has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

PTC Therapeutics has Narrow Moat: PTC Therapeutics has a solid narrow moat due to its valuable intellectual property and patents in the biotech sector. The company benefits from significant R&D capabilities and regulatory barriers, but lacks strong brand strength and customer loyalty, limiting its moat to a narrow category.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes PTC Therapeutics might have Narrow Moat - Solid narrow moat.

PTC Therapeutics  (FRA:BH3) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

PTC Therapeutics Moat Score Related Terms

FRA:BH3 vs SRRK, COGT, RYTM: Moat Score Comparison

For the Biotechnology subindustry, PTC Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PTC Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's Moat Score falls into.


FRA:BH3
52GF Score
PTC Therapeutics Inc FRA:BH3
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
PTC Therapeutics (FRA:BH3) has a Moat Score of 5 as of Jul. 09, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, PTC Therapeutics ranks #46 out of 1394 companies in the Biotechnology industry, placing it in the top 3.3%.
Is PTC Therapeutics' Moat Score too high?
PTC Therapeutics' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. PTC Therapeutics' value of 5 is 150% above this industry median. Based on the distribution chart, PTC Therapeutics ranks #46 out of 1394 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PTC Therapeutics has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does PTC Therapeutics' Moat Score compare to SRRK and COGT?
According to the Biotechnology industry distribution chart, PTC Therapeutics ranks #46 out of 1394 companies for Moat Score. This places PTC Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. PTC Therapeutics' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PTC Therapeutics's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PTC Therapeutics's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTC Therapeutics stock overvalued right now?
PTC Therapeutics (FRA:BH3) has a current Moat Score of 5. The stock's GF Value™ is €31.18, compared to a current price of €77.00 — trading 147% above its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. PTC Therapeutics' overall GF Score™ is 52/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For PTC Therapeutics (FRA:BH3), the current Moat Score is 5 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PTC Therapeutics (FRA:BH3) Overvalued in 2026?

Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued. The current stock price of €77.00 is trading 147% above its estimated GF Value™ of €31.18.

Key valuation signals for FRA:BH3:

  • Moat Score: 5
  • GF Value™: €31.18 vs. price of €77.00 (147% above fair value)
  • GF Score™: 52/100 with 9 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1394)

No single metric tells the full story. See the FRA:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PTC Therapeutics Business Description

Other Exchanges PTCT:USABH3:Germany
Address 500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
52GF Score

Get the complete analysis for FRA:BH3

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€77.00
Price
€31.18
GF Value